Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma

International Journal of Biological Markers

Volumn 26, Issue 2, 2011, Pages 82-87

  Solassol, Jérôme ^a,b   Du Thanh, Aurélie ^b,c   Maudelonde, Thierry ^a,b   Guillot, Bernard ^b,c  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UNIV MONTPELLIER   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

Biomarkers; Melanoma; Prognosis; Proteomic profiling

Indexed keywords

ALPHA N ACETYLGALACTOSAMINIDASE; LACTATE DEHYDROGENASE; PROTEIN S 100; PROTEIN S100B; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CLINICAL PRACTICE; CUTANEOUS MALIGNANT MELANOMA; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MASS SPECTROMETRY; MELANOMA; NONHUMAN; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; SKIN CANCER;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; LYMPH NODES; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SKIN NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79959310068     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8344     Document Type: Article

References (40)

1. Belot A, Grosclaude P, Bossard N, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008; 56: 159-75.
2. de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355-66.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
4. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
5. Aitchison TC, Sirel JM, Watt DC, MacKie RM. Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma. Scottish Melanoma Group. BMJ 1995; 311: 1536-9; discussion 1539-41.
6. Becker D, Mihm MC, Hewitt SM, Sondak VK, Fountain JW, Thurin M. Markers and tissue resources for melanoma: meeting report. Cancer Res 2006; 66: 10652-7.
7. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19: 739-44.
8. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature 1980; 286: 400-1.
9. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995; 37: 417-29.
10. Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol 2009; 16: 3455-62.
11. Martenson ED, Hansson LO, Nilsson B, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19: 824-31.
12. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998; 138: 426-30.
13. Hauschild A, Engel G, Brenner W, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56: 338-44.
14. Egberts F, Hitschler WN, Weichenthal M, Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res 2009; 19: 31-5.
15. Stahlecker J, Gauger A, Bosserhoff A, Buttner R, Ring J, Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 2000; 20: 5041-4.
16. Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003; 13: 45-9.
17. Smit LH, Korse CM, Hart AA, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005; 41: 386-92.
18. Acland K, Evans AV, Abraha H, et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 2002; 146: 832-5.
19. Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. Anticancer Res 2010; 30: 1799-805.
20. Hill BR, Levi C. Elevation of a serum component in neoplastic disease. Cancer Res 1954; 14: 513-5.
21. Agarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009; 45: 1807-14.
22. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16: 1103-11.
23. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17: 1891-6.
24. Mouawad R, Spano JP, Khayat D. Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Res 20: 67-76.
25. Negrier S, Saiag P, Guillot B, et al. Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report). Bull Cancer 2006; 93: 371-84.
26. Pons M, Mancheno-Corvo P, Martin-Duque P, Quintanilla M. Molecular biology of malignant melanoma. Adv Exp Med Biol 2008; 624: 252-64.
27. Findeisen P, Zapatka M, Peccerella T, et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 2009; 27: 2199-208.
28. Greco M, Mitri MD, Chiriaco F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett 2009; 283: 222-9.
29. Wilson LL, Tran L, Morton DL, Hoon DS. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann N Y Acad Sci 2004; 1022: 317-22.
30. Mian S, Ugurel S, Parkinson E, et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005; 23: 5088-93.
31. Lescuyer P, Chevallet M, Rabilloud T. Concepts and therapeutic perspectives of proteomics. Med Sci (Paris) 2004; 20: 587-92.
32. Dakna M, Harris K, Kalousis A, et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 2010; 11: 594.
33. Robin X, Turck N, Hainard A, Lisacek F, Sanchez JC, Muller M. Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? Expert Rev Proteomics 2009; 6: 675-89.
34. Dossat N, Mange A, Solassol J, et al. Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer Inform 2007; 3: 295-305.
35. Ressom HW, Varghese RS, Zhang Z, Xuan J, Clarke R. Classification algorithms for phenotype prediction in genomics and proteomics. Front Biosci 2008; 13: 691-708.
36. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3: 367-78.
37. Gillette MA, Mani DR, Carr SA. Place of pattern in proteomic biomarker discovery. J Proteome Res 2005; 4: 1143-54.
38. Li J, Orlandi R, White CN, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005; 51: 2229-35.
39. Zhang Z, Bast RC, Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90.
40. Paulitschke V, Kunstfeld R, Mohr T, et al. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res. 2009; 8:2501-10.